Skip to main content


at San Francisco, California and other locations
study started
estimated completion:



Lead survivability will be summarized.

Official Title

Attain Ability® Family Left Ventricular Lead Chronic Performance Study


The purpose of this study is to evaluate long-term performance of the 4396 LV Lead. This evaluation is based on the number of lead-related complications occurring during the study compared to the number of leads enrolled in the study. The leads will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the Model 4396 LV Lead. This study is conducted within Medtronic's post-market surveillance platform.


Heart Failure


Patients who meet all of the following inclusion criteria and do not meet any of the following exclusion criteria are eligible for enrollment.

Inclusion Criteria

  • Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
  • Patient has or is intended to receive an Attain Ability Model 4396 LV lead
  • Patient within 30 day post implant enrollment window

Exclusion Criteria

  • Patient who is, or is expected to be inaccessible for follow-up
  • Patient with exclusion criteria required by local law
  • Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results


  • University of California San Francisco UCSF Medical Center
    San Francisco, California, 94143, United States
  • Cardiovascular Consultants Medical Group
    Van Nuys, California, 91405, United States
  • Redding Heart Care
    Redding, California, 96001, United States
  • COR Healthcare
    Torrance, California, 90503, United States
  • HealthCare Partners CCNV
    Henderson, Nevada, 89052, United States
  • Eisenhower Desert Cardiology Center
    Rancho Mirage, California, 92270, United States


in progress, not accepting new patients
Start Date
Completion Date
Study Type
Last Updated
November 29, 2017